Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: A real-world experience

Bibliographic Information
Authors: El-Khayat H.R.; Fouad Y.M.; Maher M.; El-Amin H.; Muhammed H.
Journal: Gut
Publisher: BMJ Publishing Group
Publication Date: 10 August 2016
Volume / Issue: Volume 66 / Issue 11
Pages: 2008–2012
ISSN: 175749
DOI: 10.1136/gutjnl-2016-312012
Scopus: View on Scopus
PubMed: 27511197
Document Type: Article
Authors and Affiliations
El-Khayat H.R., Gastroenterology and Endemic Medicine Department, Theodore Research Institute, Cairo, Egypt; Fouad Y.M., Gastroenterology and Endemic Medicine Department, Minia University, Minia, 19111, Egypt; Maher M., Gastroenterology and Endemic Medicine Department, Ain Shams University, Cairo, Egypt; El-Amin H., Internal Medicine Department, Assuit University, Assuit, Egypt; Muhammed H., Gastroenterology and Endemic Medicine, Endemic Medicine Department, Minia University, Minia, Egypt
Abstract
Background Simeprevir plus sofosbuvir (SIM/SOF) regimen was recommended by professional guidelines for certain patients with HCV genotype 1 infection and there is lack of data about this regimen in patients with genotype 4 infection. Aim To evaluate the efficacy and safety of this regimen in Egyptian patients with chronic HCV genotype 4 infection in the real world. Methods Multicentre observational study included 583 patients with HCV genotype 4 infection who began 12â €..weeks of treatment with SIM plus SOF. Demographic, clinical and virological data as well as adverse outcomes were collected. Treatment naïve patients were 342 (59%) of all included patients, 45% of patients had severe fibrosis (F3 and F4) while 55% had mild fibrosis (F1 and F2) and the primary outcome was sustained virological response (SVR). Results The overall SVR rate was 95.7% (558 out of 583 patients). In total, SVR12 in naïve patients with mild fibrosis score (F1 and F2) was achieved in 98.9% (94/95) for F1 and 98.1% (105/107) for F2, while naïve patients with severe fibrosis (F3 and F4) achieved SVR of 97.7% (86/88) for F3 and (42/52) 80.8% for F4. SVR in patients with previous interferon treatment achieved in 100% (45/45) for patients with F1 and 98.7% (74/75) for F2. While 94.7% (72/76) in experienced patients with F3; and 88.9% (40/45) for F4 achieved SVR12. Notable side effects included rash in 21 patients, photosensitivity in 18 patients, pruritus in 44 patients and hyperbilirubinemia in 42 patients. Conclusions A 12-week regimen of simeprevir/sofosbuvir was efficacious and well tolerated by treatment-naïve and treatment-experienced patients with chronic HCV genotype 4. © Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-And-licensing/.
Keywords
CHRONIC HEPATITIS; CIRRHOSIS; HCV; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult; interferon; antivirus agent; Article; chronic hepatitis C; cohort analysis; demography; disease severity; drug efficacy; drug safety; Egyptian; gastrointestinal hemorrhage; hepatic encephalopathy; Hepatitis C virus genotype 1; Hepatitis C virus genotype 4; human; hyperbilirubinemia; liver fibrosis; major clinical study; multicenter study; observational study; photosensitivity; priority journal; pruritus; rash; scoring system; side effect; sustained virologic response; thrombocytopenia; treatment duration; clinical trial; combination drug therapy; drug administration; follow up; genetics; very elderly; virology
Citation Information
Scopus Citations: 25
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
